Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novartis AG's gross profit for the
three
months ended in Jun. 2026 was CHF8,985 Mil. Novartis AG's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was CHF33,690 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Novartis AG's gross profit for the
three
months ended in Jun. 2026 was CHF8,985 Mil. Novartis AG's Revenue for the
three
months ended in Jun. 2026 was CHF11,950 Mil. Therefore, Novartis AG's Gross Margin % for the quarter that ended in Jun. 2026 was 75.19%.
Novartis AG had a gross margin of 75.19% for the quarter that ended in Jun. 2026 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Novartis AG was 75.83%. The lowest was 64.56%. And the median was 71.82%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Novartis AG had a gross margin of 75.19% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Novartis AG Gross Profit Related Terms
Novartis AG Gross Profit Historical Data
* Premium members only.
The historical data trend for Novartis AG's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0QLR vs LLY, JNJ, ABBV: Gross Profit Comparison
For the Drug Manufacturers - General subindustry, Novartis AG's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novartis AG Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Gross Profit distribution charts can be found below:
* The bar in red indicates where Novartis AG's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF33,690 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Novartis AG (LTS:0QLR) has a Gross Profit of CHF33,690 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Novartis AG and its competitors.
Is Novartis AG's Gross Profit too high?
Novartis AG's current Gross Profit is CHF33,690 Mil. Overall, Novartis AG has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Gross Profit compare to LLY and JNJ?
Novartis AG's Gross Profit of CHF33,690 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Novartis AG and its competitors. Novartis AG's current Gross Profit is CHF33,690 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (LTS:0QLR) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF106.47, compared to a current price of CHF121.62 — trading 14.2% above its estimated fair value. The current Gross Profit is CHF33,690 Mil. Novartis AG's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Novartis AG (LTS:0QLR), the current Gross Profit is CHF33,690 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novartis AG (LTS:0QLR) Overvalued in 2026?
Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued.
The current stock price of CHF121.62 is trading 14.2% above its estimated GF Value™ of CHF106.47.
GuruFocus considers Novartis AG to be Modestly Overvalued.
Key valuation signals for LTS:0QLR:
Gross Profit: CHF33,690 Mil
GF Value™: CHF106.47 vs. price of CHF121.62 (14.2% above fair value)
No single metric tells the full story. See the LTS:0QLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
81GF Score
Get the complete analysis for LTS:0QLR
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QLR has been successfully added to your 
